Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis

Fig. 4

Change in SDAI scores in the lower 25% and upper 25% quartiles of changes in biomarkers C1M, C3M, and C4M at week 12. Patients with the greatest decrease in biomarkers (upper 25% quartile) had significantly greater improvement in SDAI scores compared to those with less of a decrease or possibly an increase in biomarkers. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 upper quartile versus lower quartile for percent improvement in SDAI score based on analysis of variance comparison. SDAI, Simplified Disease Activity Index

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us